Disclosed are 7-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide derivaives as represented by the general formula (I), in which R2 represents: alkyl, cycloalkyl-alkyl, alkylthio-alkyl, alkoxy-alkyl, hydroxy-alkyl, hydroxy-alkyl-cycloalkyl-alkyl, fluoroalkyl, alkyl-oxyimino-alkyl, cycloalkyl, fluorocycloalkyl, hydroxy-cycloalkyl, a heterocyclic group comprising a saturated carbon-based cyclic group comprising from 3 to 8 carbon atoms and at least one heteroatom chosen from nitrogen, oxygen, sulfur and the oxide or dioxide form of sulfur, an alkyl-heterocyclic group comprising a saturated carbon-based cyclic group comprising from 3 to 8 carbon atoms and at least one heteroatom chosen from nitrogen, oxygen, sulfur and the oxide or dioxide form of sulfur, X6 represents a hydrogen, fluorine, chlorine or bromine atom or alkyl, cycloalkyl, cycloalkylalkyl, fluoroalkyl or cyano R7 represents an optionally substituted phenyl or naphthyl group, and wherein the remaining substituents are as defined herein. Representative compounds include N2-tert-butyl-6-chloro-7-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide, N2-tert-butyl-6-fluoro-7-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide, N2-tert-butyl-7-(4-methoxyphenyl)-3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide, N2-6-di-cyclopropyl-7-(4-methoxyphenyl)-3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide, 6-cyclopropyl-7-(4-methoxyphenyl)-N2-(isopropyl)-3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide, N2-tert-butyl-6-cyclopropyl-7-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide, 6-chloro-N2-iso-butyl-7-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide and 6-chloro-7-(3-fluorophenyl)-N2-{ [1-(hydroxymethyl)cyclopropyl]methyl} -3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide. Also disclosed is a medicament comprising a compound of formula (I) as defined above, in the form of the base or of an ad
